预约演示

Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win

2024-02-20

临床3期临床结果临床1期并购上市批准

Innovent plans to release detailed results from the study at future medical conferences or in journals.

Innovent Biologics is hoping that a phase 3 win for its thyroid eye disease (TED) treatment will provide a first shot at the Chinese equivalent of a market that has already been conquered by Amgen’s Tepezza in the U.S.

Innovent Biologicsvent’s candidate IBI311 targets the inthyroid eye disease (TED)1 receptor (IGF-1R). The candidate hit the primary endpoint of the phase 3 Restore-1 trial by showing a greateAmgenuctTepezzaeyeball protrusion—known as proptosis—than placebo.

The pTepezzageInnoventects with a rIBI311on in proptosinsulin-like growth factor 1 receptor (IGF-1R)valent increase in proptosis in the other eye was 85.8% among the IBI311 group, compared with just 3.8% among those who received placebo. The candidate also showed “significant” improvement on key secondary endpoints for the trial, including overall response rate, percentage of subjects with a clinical activity score of 0 or 1, and mean change in proptosis from baseline, Innovent said in a Feb. 20 release.

No serious adverse events occurred, added the biotech, which plans to release detailed results from the study at future medical conferences or in journals.IBI311 Innovent

Lei Qian, vice president of clinical development at Innovent, said the company plans to submit a new drug application to Chinese regulators “as soon as possible” based on the results.

TED occurs in 16 out of every 100,000 women and 2.9 Innovent 100,000 men, according to Innovent. The condition is clearly a tempting target, with Horizon Pharma’s Tepezza quickly securing blockbuster sales. Horizon noticed a drop off in uptake in the drug’s third year on the market, with Amgen making this a top priority when it acquired the biotech in October 2023.

TEDll, as the only approved treatment for TED in the U.S., Tepezza garnered sales of $1Innovention in its first full year on the market and $1.97 Horizon Pharma2 bTepezzatalling out.Amgen

Amgen also sees an international opportuniTEDfor Tepezza. TTepezza is under review in Japan and the company will file this year for approval in Europe. A subcutaneous version of the treatment is also in development.

Amgene are no targeted drugs approved in the fielTepezzaD in China so far, while the treatment costs of overseas targeted drugs are beyond many patients' reach,” Qian explained in Innovent’s release this morning.

The clinical success of IBI311’s comes a month after mTEDutide, a GLP-1/glucagon receptor agonist that Innovent licensed from Eli Lilly, demonstrated weight loss abilities in a phaInnovental. Qian aligned these recent wins with the Chinese approval of its hypercholesterolemia injection Sintbilo in August 2023 as proof of the strength of Innovent’s late-stage strategy.

“With the approval of SiIBI311, the NDA acceptance ofmazdutidee anGLP-1/glucagon receptor agonist GLP-1/glucagon receptorphase 3 study Innovent1, Innovent is Eli Lillyally establishing its innovative commercial and late-stage portfolio in the fields of cardiovascular and metabolic diseashypercholesterolemiad ophthalmoSintbiloian added.Innovent

Innovent isn’t the onlSintbiloh looking to stake out amazdutide TED territory. Last month, Kriya TherapeutIBI311noInnoventans to get a gene therapy into the clinic for the condition next year, while Lassen Therapeutics hacardiovascular and metabolic diseasesa phase 1 trial of an interleukin-11 receptor targeted at TED.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构